Drugs / RSV/hMPV vaccine candidate
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06134648 | Nov 2023 → Feb 2026 | respiratory syncytial virus infectious disease | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RSV/hMPV vaccine candidate | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06134648 ↗ |
| Modality | Vaccine | “RSV/hMPV vaccine candidate” NCT06134648 ↗ |
| Route | Intramuscular | “Route of administration:Intramuscular Injection” NCT06134648 ↗ |